The rate of severe neurotoxicity (grade 3 or greater) was 30% for axicabtagene ciloleucel in refractory/relapsed B-cell lymphoma5, 21% for anti-CD19 CART clinic trial in ALL led by Fred Hutchinson Cancer Research Center (FHCRC)6, and 42% for anti-CD19 CART clinic trial in ALL led by Memorial Sloan Kettering Cancer Center (MSKCC)7. The gene discussed is CD19; the disease is acute lymphoblastic leukemia.